Intracellular angiotensin II activates rat myometrium

Am J Physiol Cell Physiol. 2011 Sep;301(3):C559-65. doi: 10.1152/ajpcell.00123.2011. Epub 2011 May 25.

Abstract

Angiotensin II is a modulator of myometrial activity; both AT(1) and AT(2) receptors are expressed in myometrium. Since in other tissues angiotensin II has been reported to activate intracellular receptors, we assessed the effects of intracellular administration of angiotensin II via microinjection on myometrium, using calcium imaging. Intracellular injection of angiotensin II increased cytosolic Ca(2+) concentration ([Ca(2+)](i)) in myometrial cells in a dose-dependent manner. The effect was abolished by the AT(1) receptor antagonist losartan but not by the AT(2) receptor antagonist PD-123319. Disruption of the endo-lysosomal system, but not that of Golgi apparatus, prevented the angiotensin II-induced increase in [Ca(2+)](i). Blockade of AT(1) receptor internalization had no effect, whereas blockade of microautophagy abolished the increase in [Ca(2+)](i) produced by intracellular injection of angiotensin II; this indicates that microautophagy is a critical step in transporting the peptide into the endo-lysosomes lumenum. The response to angiotensin II was slightly reduced in Ca(2+)-free saline, indicating a major involvement of Ca(2+) release from internal stores. Blockade of inositol 1,4,5-trisphosphate (IP(3)) receptors with heparin and xestospongin C or inhibition of phospholipase C (PLC) with U-73122 abolished the response to angiotensin II, supporting the involvement of PLC-IP(3) pathway. Angiotensin II-induced increase in [Ca(2+)](i) was slightly reduced by antagonism of ryanodine receptors. Taken together, our results indicate for the first time that in myometrial cells, intracellular angiotensin II activates AT(1)-like receptors on lysosomes and activates PLC-IP(3)-dependent Ca(2+) release from endoplasmic reticulum; the response is further augmented by a Ca(2+)-induced Ca(2+) release mechanism via ryanodine receptors activation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Angiotensin II / administration & dosage
  • Angiotensin II / metabolism*
  • Angiotensin II / pharmacology
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin II Type 2 Receptor Blockers / pharmacology
  • Animals
  • Arsenicals / pharmacology
  • Autophagy / drug effects
  • Brefeldin A / pharmacology
  • Calcium Signaling / drug effects
  • Calcium Signaling / physiology*
  • Carbolines / pharmacology
  • Cells, Cultured
  • Egtazic Acid / pharmacology
  • Endocytosis / drug effects
  • Endoplasmic Reticulum / drug effects
  • Endoplasmic Reticulum / metabolism
  • Endosomes / metabolism
  • Enzyme Inhibitors / pharmacology
  • Estrenes / pharmacology
  • Female
  • Heparin / pharmacology
  • Imidazoles / administration & dosage
  • Imidazoles / pharmacology
  • Inositol 1,4,5-Trisphosphate Receptors / antagonists & inhibitors
  • Inositol 1,4,5-Trisphosphate Receptors / metabolism
  • Losartan / administration & dosage
  • Losartan / pharmacology
  • Lysosomes / metabolism
  • Macrocyclic Compounds / pharmacology
  • Macrolides / pharmacology
  • Models, Biological
  • Myometrium / cytology
  • Myometrium / drug effects
  • Myometrium / metabolism*
  • NADP / analogs & derivatives
  • NADP / metabolism
  • Oxazoles / pharmacology
  • Piperazines / pharmacology
  • Pyridines / administration & dosage
  • Pyridines / pharmacology
  • Pyrrolidinones / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Angiotensin, Type 1 / metabolism
  • Receptor, Angiotensin, Type 2 / metabolism
  • Ryanodine / pharmacology
  • Saralasin / administration & dosage
  • Saralasin / pharmacology
  • Signal Transduction / drug effects
  • Signal Transduction / physiology*
  • Sirolimus / pharmacology
  • Type C Phospholipases / antagonists & inhibitors
  • Type C Phospholipases / metabolism
  • Uterus / cytology

Substances

  • 1-(3-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido(3,4-b)indole-3-carboxylic acid
  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin II Type 2 Receptor Blockers
  • Arsenicals
  • Carbolines
  • Enzyme Inhibitors
  • Estrenes
  • Imidazoles
  • Inositol 1,4,5-Trisphosphate Receptors
  • Macrocyclic Compounds
  • Macrolides
  • Oxazoles
  • Piperazines
  • Pyridines
  • Pyrrolidinones
  • Receptor, Angiotensin, Type 1
  • Receptor, Angiotensin, Type 2
  • xestospongin C
  • oxophenylarsine
  • Angiotensin II
  • 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione
  • PD 123319
  • Ryanodine
  • Brefeldin A
  • Egtazic Acid
  • NADP
  • NAADP
  • bafilomycin A1
  • Heparin
  • Type C Phospholipases
  • Saralasin
  • Losartan
  • Sirolimus